Refractory, advanced Mycosis fungoides Not Yet Recruiting Phase 1 Trials for Brentuximab vedotin (DB08870)

Also known as: Refractory advanced Mycosis fungoides / Mycosis fungoides refractory / Refractory Mycosis Fungoides

IndicationStatusPhase
DBCOND0024424 (Refractory, advanced Mycosis fungoides)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03373305Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasTreatment